Life Sciences Seminar: Bad Blood (feat. organ-on-chip): Recreating the bone marrow in the lab to study acute myeloid leukemia
Life Science Seminar
Bad Blood (feat. organ-on-chip): Recreating the bone marrow in the lab to study acute myeloid leukemia
Azmeer Sharipol, (RIT Biotechnology ’17)
Ph.D. Candidate and NCI F99 Fellow, Biomedical Engineering
University of Rochester Medical Center
Abstract: Acute myeloid leukemia (AML) is an aggressive blood cancer that starts in the bone marrow. Current therapies for AML result in a 5-year survival rate of ~30%, highlighting the need for safer and more effective therapies. During AML, leukemia cells over-accumulate in the bone marrow and change the function of the surrounding cells to create a favorable environment for leukemia cell survival. The dysregulation of the bone marrow causes loss of normal hematopoiesis and is associated with the mortality and morbidity of AML. Our research goal is to develop a clinically relevant 3D model of the leukemic bone marrow microenvironment that can recapitulate the phenotypes of AML. We utilize a combination of organ-on-chip, microfluidics, and hydrogel technologies to successfully replicate the bone marrow that can maintain blood stem cell function and mimic the dysregulation due to leukemia cells.
Intended Audience: All are Welcome!
To request an interpreter, please visit myaccess.rit.edu
Event Snapshot
When and Where
Who
This is an RIT Only Event
Interpreter Requested?
No